Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-18
2005-10-18
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06956051
ABSTRACT:
The present invention relates to amphiphilic drug-oligomer conjugates capable of traversing the blood-brain barrier (“BBB”) and to methods of making and using such conjugates. An amphiphilic drug-oligomer conjugates comprise a therapeutic compound conjugated to an oligomer, wherein the oligomer comprises a lipophilic moiety coupled to a hydrophilic moiety. The conjugates of the invention further comprise therapeutic agents such as proteins, peptides, nucleosides, nucleotides, antiviral agents, antineoplastic agents, antibiotics, etc., and prodrugs, precursors, derivatives and intermediates thereof, chemically coupled to amphiphilic oligomers.
REFERENCES:
patent: 3256153 (1966-06-01), Heimlich
patent: 4003792 (1977-01-01), Mill et al.
patent: 4044196 (1977-08-01), Hüper et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4410547 (1983-10-01), Ueno et al.
patent: 4537878 (1985-08-01), Plotnikoff
patent: 4585754 (1986-04-01), Meisner et al.
patent: 4622392 (1986-11-01), Hong et al.
patent: 4684524 (1987-08-01), Eckenhoff et al.
patent: 4698264 (1987-10-01), Steinke
patent: 4717566 (1988-01-01), Eckenhoff et al.
patent: 4744976 (1988-05-01), Snipes et al.
patent: 4772471 (1988-09-01), Vanlerberghe et al.
patent: 4797288 (1989-01-01), Sharma et al.
patent: 4840799 (1989-06-01), Appelgren et al.
patent: 4849405 (1989-07-01), Ecanow
patent: 4935246 (1990-06-01), Ahrens
patent: 4939174 (1990-07-01), Shashoua
patent: 4963367 (1990-10-01), Ecanow
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5055300 (1991-10-01), Gupta
patent: 5055304 (1991-10-01), Makino et al.
patent: 5061691 (1991-10-01), Yagi et al.
patent: 5093198 (1992-03-01), Speaker et al.
patent: 5286637 (1994-02-01), Veronese et al.
patent: 5428128 (1995-06-01), Mensi-Fattohi et al.
patent: 5539063 (1996-07-01), Hakimi et al.
patent: 5545719 (1996-08-01), Shashoua et al.
patent: 5559213 (1996-09-01), Hakimi et al.
patent: 5571795 (1996-11-01), Kahne et al.
patent: 5595732 (1997-01-01), Hakimi et al.
patent: 5602099 (1997-02-01), Schiller
patent: 5631263 (1997-05-01), Portoghese et al.
patent: 5641861 (1997-06-01), Dooley et al.
patent: 5653987 (1997-08-01), Modi et al.
patent: 5663295 (1997-09-01), Moreau et al.
patent: 5681811 (1997-10-01), Ekwuribe
patent: 5693769 (1997-12-01), Kahne et al.
patent: 5747646 (1998-05-01), Hakimi et al.
patent: 5786447 (1998-07-01), Schiller et al.
patent: 5792834 (1998-08-01), Hakimi et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 6309633 (2001-10-01), Ekwuribe et al.
patent: WO 93/01802 (1993-02-01), None
Online-Medical Dictionary. “Amino acid”. http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=amino+acid. Nov. 13, 1997.
Alyautdin, R.N., “Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles,” Pharm. Res. J., 1997, 14: 325-328.
Aoshima, M. et al., “N4-Behenoyl-1-β-D-Arabinofuranosylcytosine as a Potential New Antitumor Agent,” Cancer Research, 1977, 37: 2481-2486.
Banting, R. G., et al., “Pancreatic Extracts in the Treatment of Diabetes Mellitus,” The Canadian Med. Assoc. J. 1922, 12: 141-146.
Baker, D. C. et al., “Prodrugs of 9-β-D-Arabinofuranosyladenine. 1. Synthesis and Evaluation of Some 5′-(O-Acyl) Derivatives,” J. Med. Chem., 1978, 21(12): 1218-1221.
Banks, W.A., et al., “Passage of Peptides Across the Blood-Brain Barrier: Pathophysiological Perspectives,” Life Sciences, 1996, 59 (23), 1923-1943.
Boccu, E. et al., “Pharmocokinetic Properties of Polyethylene Glycol Derivatized Superoxide Dismutase,” Pharm. Res. Comm., 1982, 14: 11-120.
Bodor, N., et al., “A Strategy for Delivering Peptides into the Central Nervous System by Sequential Metabolism,” Science, 1992, 257, 1698-1702.
Bodor, N., et al., “Molecular Packaging. Peptide Delivery to the Central Nervous System by Sequential Metabolism,” Amer. Chem. Soc., 1995: 317-337.
Brange, J. et al., “Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations,” Pharm. Res., 1992, 9 (6): 715-726.
Brange, J. et al., “Chemical Stability of Insulin. 2. Formation of Higher Molecular Weight Transformation Products During Storage of Pharmaceutical Preparations,” Pharm. Res., 1992, 9 (6): 727-734.
Brewster, M.E., et al., “Effect of Molecular Manipulation on the Estrogenic Activity of a Brain-Targeting Estradiol Chemical Delivery System,” J. Med. Chem., 1994, 37: 4237-4244.
Brewster, M.E., et al., “Efficacy of a 3-Substituted Versus 17-Substiturted Chemical Delivery System for Estradiol Brain Targeting,” J. Pharm. Sci., 1994: A-E.
Brewster, M., et al., “Tissue Distribution of LY231617, an Antioxidant with Neuroprotectant Activity, in the Rat,” J. Pharm. Studies, 1995, 84 (7): 791-793.
Conradi, R.A., et al., “The Influence of Peptide Structure on Transport Across Caco-2 Cells,” Pharm. Res., 1991, 8 (12): 1453-1459.
Chen, C., et al., “Extensive Biliary Excretion of the Model Opioid Peptide [D-PEN2,5] Enkephalin in Rats,” Pharm. Res. J., 14: 345-350.
Chiou, G.C.Y., et al., “Systemic Delivery of Enkephalin Peptide through Eyes,” Life Sciences, 1988, 43: 509-514.
Chun., W., et al., “Transmucosal Delivery of Methionine Enkephalin. I: Solution Stability and Kinetics of Degradation in Various Rabbit Mucosa Extracts,” J. Pharm.Sci., 1993, 82 (4): 373-378.
Fix, J.A., “Oral Controlled Release Technology for Peptides: Status and Future Prospects,” Pharm. Res., 1996, 13 (12): 1760-1763.
Gibson, A.M., et al., “Specificity of Action of Human Brain Alanyl Aminopeptidase on Leu-Enkephalin and Dynorphin-Related Peptides,” Neuropeptides, 1989, 13: 259-262.
Gish, D. T. et al., “Nucleic Acids. 11. Synthesis of 5′-Esters of 1-β-D-Arabinofuranosylcytosine Processing Antileukemic and Immunosuppressive Activity,” J. Med. Chem., 1971, 14(12): 1159-1162.
Hong, C. I. et al., “Nucleoside Conjugates. 7. Synthesis and Antitumor Activity of 1-β-D-Arabinofuranosylcytosine Conjugates of Ether Lipids,” J. Med. Chem., 1986, 29: 2038-2044.
Horvat, J., et al., “Synthesis and Biological Activity of [Leu5] Enkephalin Derivatives Containing D-Glucose,” J. Peptide Protein Res., 1988, 31: 499-507.
Hostetler, K. Y. et al., “Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides,” The Journal of Biological Chemistry, 1990, 265(11): 6112-6117.
Kroll, R.A., et al., “Outwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and Other Means,” 1998 Neurosurgery, 42 (5): 1083-1100.
Maislos, M. et al., “The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin,” J. Clin. Invest., 1986, 77: 717-723.
Mosnaim, A.D., et al., “Studies of the in Vitro Human Plasma Degradation of Methionine-Enkephalin,” Gen. Pharmac., 1988, 19 (5): 729-733.
Nestor, J., “Improved Duration of Action of Peptide Drugs,” Amer. Chem Soc. 1995: 449-471.
Oka, K. et al., “Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation,” Pharm. Res., 1990, 7 (8): 852-855.
Pardridge, W.M., “Blood-Brain Barrier Peptide Transport and Peptide Drug Delivery to the Brain,” Amer. Chem Soc. 1995: 265-296.
Pardridge, W.M., “CNS Drug Design Based on Principles of Blood-Brain Barrier Transport,” J. Neurochem., 1998, 70 (5): 1781-1792.
Pardridge, W.M., “New Approaches to Drug Delivery Through the Blood-Brain Barrier,” Trends in Biotechnology, 1994: 239-245.
Prokai-Tatrai, K., et al., “Brain-Targeted Delivery of a Leucine-Enkephalin Analogue by Retrometabolic Design,” J. Med. Chem 39 (24).
Ratner, R. E. et al., “Persistent Cutaneous Insulin Aller
Anderson Jr. Wes
Ansari Aslam M.
Ekwuribe Nnochiri N.
Price Christopher H.
Rhadakrishnan Balasingam
Audet Maury
Barrett William A.
Moore & Van Allen PLLC
Nobex Corporation
Tate Christopher R.
LandOfFree
Enkephalin conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enkephalin conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enkephalin conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3464584